[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-fatigue-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-fatigue-syndrome":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,44,70,90,116,144,174,200,227,249,272,311,333],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100344043","phase-1-assessment-of-neuroinflammation-in-central-inflammatory-disorders-using-f-18dpa-714-100344043",false,"NCT03759522","Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.","Inclusion Criteria:\n\n1. 18 to 65 years of age\n2. Healthy volunteer OR Clinical diagnosis of Multiple Sclerosis (MS) OR Meets 2016 American College of Rheumatology (ACR) case definition criteria for fibromyalgia OR Meets 1994 Fukuda case definition criteria for Chronic Fatigue Syndrome\n\nExclusion Criteria:\n\n1. Contraindication to MRI\n2. Pregnancy\n3. Lactation\n4. Individuals who are unable to participate in the imaging portion due to severity of their medical condition\n5. Chronic infectious disease (e.g. HIV, HCV)\n6. Viral or bacterial illness requiring medical attention and\u002For antibiotics within 1 month of study participation\n7. Diagnosis of cancer, including leukemia\n8. Blood or blood clotting disorder\n9. Except for individuals with MS, a diagnosis of autoimmune disease is exclusionary\n10. Positive urine β-hCG test day of procedure or a serum -hCG test within 48 hours prior to the administration of \\[18F\\]DPA-714\n11. Currently enrolled in a clinical trial utilizing experimental therapies",true,"ALL","18 Years","65 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The primary objective of this study is to measure the concentration and the regional brain distribution of activated brain microglia\u002Fmacrophages using the PET radiopharmaceutical \\[F-18\\]DPA-714 in individuals with chronic pain and fatigue suspected to be associated with neuroinflammation. The PET tracer \\[F-18\\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia\u002Fmacrophages and provides a non-invasive measure of neuroinflammation. The primary objective of this study is to determine if pain and fatigue patients have higher levels of neuroinflammation than HC individuals as measured with \\[F-18\\]DPA-714-PET\u002FMRI.",[27,28,29,30],"Fibromyalgia","Chronic Fatigue Syndrome","Multiple Sclerosis","Healthy","RECRUITING","2026-05-30",{"date":34,"type":35},"2026-06-02","ACTUAL",{"date":37,"type":35},"2019-02-03",{"date":39,"type":21},"2028-04",{"name":41,"class":42},"University of Alabama at Birmingham","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100639749","hyperbaric-oxygen-therapy-for-chronic-fatigue-syndrome-cfs-100639749","NCT07621068","Hyperbaric Oxygen Therapy for Chronic Fatigue Syndrome (CFS)","Hyperbaric Oxygen Therapy for Chronic Fatigue Syndrome (CFS) - A Prospective, Randomized, Double-Blind, Sham-Controlled Study","Inclusion Criteria:\n\n* Subject willing and able to read, understand and sign an informed consent\n* Diagnosis of mild to moderate severity of Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome\n* Patients diagnosed with CFS for more than 1 years\n* Stable psychological and pharmacological treatment for more than three months prior to inclusion\n\nExclusion Criteria:\n\n1. Inability to attend scheduled clinic visits and\u002For comply with the study protocol\n2. Severe and very severe cases of ME\u002FCFS\n3. History or diagnosis of, brain tumors, brain surgery, epilepsy, neurodegenerative diseases\n4. Active malignancy\n5. Substance use at baseline, except for prescribed cannabis if vaporized or taken PO as tincture\n6. Active smokers\n7. Chronic heart failure with ejection fraction of 30 or less\n8. Chest pathology incompatible with pressure changes (including active asthma or COPD)\n9. Ear or Sinus pathology incompatible with pressure changes (above 3 otolaryngologist visits a year)\n10. Pregnancy\n11. An inability to perform an awake brain MRI\n12. An inability to perform Neurotrax\n13. Participation in another medical study\n14. HBOT for any reason prior to study enrolment",{"count":52,"type":21},74,[54],"NA","This study evaluates the effects of hyperbaric oxygen therapy (HBOT) in patients with mild to moderate CFS\u002FME. Participants will undergo 60 HBOT sessions over 3 months with a 3-month follow-up, including physical, cognitive, imaging, and laboratory assessments.",[28],[58,59],"Hyperbaric oxygen therapy","Myalgic Encephalomyelitis","NOT_YET_RECRUITING","2026-05-27",{"date":34,"type":35},{"date":64,"type":21},"2026-06",{"date":66,"type":21},"2027-06",{"name":68,"class":69},"Assaf-Harofeh Medical Center","OTHER_GOV",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":86,"leadSponsor":88,"locationsCount":43},"100635385","a-study-of-remote-voice-analysis-tool-for-diagnosing-and-monitoring-mecfs-100635385","NCT07551999","A Study Of Remote Voice Analysis Tool For Diagnosing And Monitoring ME\u002FCFS","Use Of A Remote Voice Analysis Tool For Diagnosing And Monitoring Myalgic Encephalomyelitis\u002F Chronic Fatigue Syndrome (ME\u002FCFS)","Inclusion Criteria:\n\n* Diagnosis of myalgic encephalomyelitis\u002Fchronic fatigue syndrome (ME\u002FCFS) verified by an ME\u002FCFS specialist.\n* Ability to complete study questionnaires and provide voice samples using a smartphone application.\n* Consistent access to a smartphone or tablet with iOS or Android operating systems, or a laptop.\n\nExclusion Criteria:\n\n* No diagnosis of myalgic encephalomyelitis\u002Fchronic fatigue syndrome (ME\u002FCFS); \"Chronic Fatigue Syndrome\" not verified by an ME\u002FCFS specialist.\n* Lack of consistent access to a smartphone or tablet with iOS or Android operating systems, or laptop.\n* Known dementia or other neurodegenerative disorder prominently affecting cognition or speech patterns. outside of ME\u002FCFS\n* Known history of voice disorder either primary or secondary to neuromuscular or other pathology outside of ME\u002FCFS\n* Known clinically significant heart failure or greater than moderate pulmonary hypertension.",{"count":78,"type":21},40,"OBSERVATIONAL","The purpose of this research is to evaluate the use of a voice-based tool in the diagnosis and management of myalgic encephalomyelitis\u002Fchronic fatigue syndrome (ME\u002FCFS).",[82,28],"Encephalomyelitis","2026-05-26",{"date":61,"type":35},{"date":83,"type":35},{"date":87,"type":21},"2028-07",{"name":89,"class":42},"Mayo Clinic",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":43},"100529197","transcutaneous-vagus-nerve-stimulation-as-a-complementary-therapy-to-exercise-in-chronic-fatigue-100529197","NCT06170645","Transcutaneous Vagus Nerve Stimulation as a Complementary Therapy to Exercise in Chronic Fatigue","Transcutaneous Vagus Nerve Stimulation as a Complementary Therapy to Exercise in Chronic Fatigue: Single-center, Controlled, Randomized, Blinded Study","PAF-tVNS","Inclusion Criteria:\n\n* Patient over 18 years old\n* Signature of informed consent\n* Confirmed diagnosis of fibromyalgia or long Covid (ACR 2016 criteria and persistent symptoms lasting more than 6 months after a positive RT-PCR test, respectively)\n* Persistent fatigue after an exercise rehabilitation program (FSS score \\> 36)\n* Physical inactivity, i.e. \\\u003C150 minutes per week of physical activity\n\nExclusion Criteria:\n\n* Pre-existing atrial fibrillation,\n* Left ventricular ejection fraction \\\u003C40%\n* Severe heart failure\n* Recent stroke or myocardial infarction (\\\u003C6 months)\n* Unilateral or bilateral vagotomy\n* Pregnancy or breastfeeding",{"count":99,"type":21},60,[54],"Chronic fatigue is enhanced by adapted physical activity (APA) programs. Patients consulting on St Etienne hospital and suffering from fibromyalgia and long Covid benefit from a 4-6 week APA program, with 2 sessions per week. While most patients are improved by these exercise-training programs, for some the benefits remain very modest, and patients describe persistent fatigue. The literature unanimously describes the necessity of longer APA protocols (8-12 weeks, 2-3 sessions\u002Fweek) for fatigue reduction in fibromyalgia and long Covid. However, it seems difficult to adhere to an optimal program as described in the literature for these fatigued patients. The investigators want to test a device that would both reduce fatigue and improve recovery between APA sessions, in order to gradually reach the recommendations for APA practice. Transcutaneous vagal nerve stimulation (tVNS) seems to be a promising approach. Thus, combining an APA intervention with a tVNS protocol could potentiate the expected and now well-known effect of exercise.",[28],[104,105,106],"Chronic fatigue","Transcutaneous vagal nerve stimulation (tVNS)","adapted physical activity (APA)","2026-05-05",{"date":109,"type":35},"2026-05-06",{"date":111,"type":35},"2024-10-03",{"date":113,"type":21},"2028-08",{"name":115,"class":42},"Centre Hospitalier Universitaire de Saint Etienne",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":43},"100555358","phase-1-lumbrokinase-for-adults-with-long-covid-post-treatment-lyme-disease-syndrome-and-myalgic-encephalomyelitischronic-fatigue-syndrome-100555358","NCT06511050","Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome","Investigating the Effects of Lumbrokinase in Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome","Inclusion Criteria:\n\n* Any gender\n* Aged 18+\n* Baseline EQ-VAS ≤70; EQ-VAS before the index infection ≥80 (this information is collected as part of the baseline survey).\n* Diagnosed with only one of the following conditions:\n* Long Covid\n* Documented clinical history of confirmed or suspected acute COVID-19 infection a minimum of 3 months prior to contact with the study team\n* Formal diagnosis of Long Covid from a physician\n* Post-treatment Lyme disease syndrome\n* Diagnosis will be based on participants meeting either Group 1 or Group 2 criteria of the Columbia Clinical Trial Network PTLDS diagnostic criteria:\n\n  * Group 1. Well-defined Lyme disease meeting CDC Surveillance Definition Erythema Migrans History of possible exposure to a high incidence county or state (or an adjacent area) Erythema migrans rash\n\n    * EM 1: EM rash diagnosed by HCP previously (either in person or telemedicine)\n    * EM 1A: MOA self-report \\& medical record documentation of rash \\> 5 cm\n    * EM 1B: MOA: self-report and medical record documentation of EM rash but not size\n    * EM 1C: MOA: self-report \\& rash misdiagnosed in medical record as cellulitis\u002Fspider bite\n    * EM 1D: MOA: self-report and either: photo of EM or Class 1 lab test confirmation within 4 weeks of illness onset OR\n    * Disseminated \"objective\" manifestation with lab test confirmation of Bb infection\n    * Clinical history includes at least one of the following symptoms\u002Fsigns, which are not better accounted for by another cause (MOA: medical records and\u002For self-report).\n    * Neurologic: Lymphocytic Meningitis ; Encephalitis; Encephalomyelitis Cranial Neuritis (especially facial palsy); Radiculoneuropathy; Other Neurologic Signs (with objective measures) : Encephalopathy, Polyneuropathy\n    * Carditis: 2nd or 3rd degree AV block; Myocarditis; Pericarditis\n    * Lyme arthritis: Recurrent joint swelling in one or more joints\n    * Dermatologic: Disseminated EM (\"satellite\") or Acrodermatitis atrophicans AND\n    * Lab test Confirmation (requires at least one of the Class 1 lab tests) (MOA: self-report \\& documentation)\n  * Group 2. Probable\n\n    * 2A. Chronic Multisystem Symptoms attributed to Lyme disease (insufficient to meet Group 1) and not better explained by another diagnosis and patient has evidence of positive lab results on a Class 1 lab test (or 4 of 10 bands for IgG Western blot (WB)) (MOA: self-report with lab documentation Class 1 lab test confirmation (excluding IgM WB) Highly suggestive IgG WB (4 of 10 bands) OR\n    * 2B. EM rash by history after exposure to a Lyme-endemic area but not previously diagnosed by a HCP and no photo or Class 1 lab test confirmation is available (MOA: self-report) OR\n    * 2C. Viral like illness (not better explained by other cause) with indeterminate or + enzyme immunoassay (EIA) with positive IgM WB or positive Class 1 lab test (within 4 weeks of illness onset after known exposure to a Lyme high-incidence area for standard two-tiered (STT) IgM) (MOA: medical records, lab test and self-report) (MOA: lab test and self-report) OR\n    * 2D. Viral like illness (not better explained by other cause) with indeterminate or positive EIA with positive IgM WB or positive Class 1 lab test (within 6 months of illness onset after known exposure to a Lyme high-incidence area for standard two-tiered (STT) IgM)\n* (MOA: medical records, lab test and self-report)\n* (MOA: lab test and self-report)\n* ME\u002FCFS\n* Formal diagnosis of ME\u002FCFS prior to 2020 from a physician\n* Actively symptomatic such that the 2011 International Criteria for ME\u002FCFS is met at time of screening\n\nExclusion Criteria:\n\n* Current use of antiplatelet or anticoagulation regimen\n* Diagnosis of an autoimmune condition such as Chronic EBV, Multiple Sclerosis, Hashimoto's Disease, etc. which would impact the immunological profiling analysis.\n* Pregnancy or lactation\n* Known allergy to earthworms (Lumbrokinase is a supplement that is derived from earthworms)\n* Past medical history of a bleeding or clotting disorder\n* Has a scheduled surgery during, or immediately after, the study period",{"count":20,"type":21},[24,125],"PHASE2","This will be a pilot multi-arm clinical trial investigating the feasibility of Lumbrokinase (LK) as an intervention in three clinical cohorts:\n\n* Long Covid (LC)\n* Post-treatment Lyme disease syndrome (PTLDS)\n* Myalgic encephalomyelitis\u002Fchronic fatigue syndrome (ME\u002FCFS)",[128,129,28,59],"Long Covid","Post-treatment Lyme Disease Syndrome",[128,131,132,133,134],"Lyme Disease","ME\u002FCFS","Lumbrokinase","Post-treatment Lyme disease syndrome","2026-03-11",{"date":137,"type":35},"2026-03-13",{"date":139,"type":35},"2024-10-09",{"date":141,"type":21},"2026-12",{"name":143,"class":42},"Icahn School of Medicine at Mount Sinai",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":43},"100457428","a-3-day-course-for-cfsme-100457428","NCT05236465","A 3-day Course for CFS\u002FME","A 3-day Course for Adults With Chronic Fatigue Syndrome\u002FMyalgic Encephalopathy (CFS\u002FME): a Randomized Controlled Trial","Inclusion Criteria:\n\n* CFS\u002FME diagnosis based on the Canada Consensus Criteria.\n* At least 50% out of school\u002Fwork.\n* Readiness to change (corresponding to the preparation phase in transtheoretical model)\n* Has given informed consent.\n\nExclusion Criteria:\n\n* Assessed by a General Practitioner (GP):\n* Underlying physical illness or mental disorder that may explain the symptoms.\n* Suicide risk\u002Fprevious suicide attempts.\n* Pregnancy.\n* Bedridden and in need of continuous care.\n* Insufficient Norwegian speaking or writing skills to participate in the 3-day course and fill out questionnaires.",{"count":152,"type":21},100,[54],"Chronic fatigue syndrome\u002FMyalgic encephalomyelitis (CFS\u002FME) can be a serious and disabling condition with a heavy symptom burden and low function. Work disability is common, and social life dramatically affected. CFS\u002FME is a challenging health problem as well as a societal problem.\n\nIn recent years, a doubling of the number of patients with a CFS\u002FME diagnoses has been reported in Norway. The patient group represents a challenge for the health care system, the municipality, and the Norwegian Labour and Welfare Organization (NAV). According to new figures, the NAV pays 100 million Norwegian Kroner (NOK) each month in permanently incapacitated expenses for people with CFS\u002FME. Municipalities have expenses in form of care, rehabilitation and other measures.\n\nThere is a lack of effective treatment for CFS\u002FME. Evidence-based knowledge is highly needed.\n\nIf the 3-day course shows promising effects, this could have positive consequences for patients, relatives and health personnel, but also financially for the society and the municipality.",[28,59],[157,158,159,160,161,162,163,164],"Health education","Chronic Fatigue Syndrome\u002FMyalgic Encephalopathy (CFS\u002FME)","RCT","3-day Course","Physical function","Fatigue","Cognitive techniques","Behavioral activation","2025-11-25",{"date":167,"type":35},"2025-11-26",{"date":169,"type":35},"2022-03-21",{"date":171,"type":21},"2028-12-01",{"name":173,"class":42},"Norwegian University of Science and Technology",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":181,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":43},"100561061","tvns-in-long-covid-19-100561061","NCT06585254","tVNS in Long COVID-19","Use of Transcutaneous Vagus Nerve Stimulation in Reducing the Symptoms of Long COVID Patients Who Fulfill Diagnostic Criteria for ME\u002FCFS","Inclusion Criteria:\n\n* Must have had documented Covid infection and then fulfill 2015 case definition for ME\u002FCFS\n* Chalder Fatigue Scale score of 4 or greater\n* SF-36 Physical Function scale score ≤70\n* VAS values of 3 or higher from 0 \\[none\\] 3 \\[substantial\\] to 5 \\[very severe burden\\] on at least two of the following symptoms - fatigue; widespread pain, brain fog, post-exertional malaise\n\nExclusion Criteria:\n\n* BMI ≥30\n* Hospitalized for COVID-19 infection\n* BMI ≥30\n* Pregnancy","21 Years","70 Years",{"count":184,"type":21},50,[54],"A prior open label study has shown that transcutaneous vagus nerve stimulation \\[tVNS\\] can improve the health of some patients with postacute sequelae of SARS-CoV-2 infection (PASC), severely affected enough to also fulfill criteria for myalgic encephalomyelitis \u002F chronic fatigue syndrome (ME\u002FCFS). The purpose of this study is to compare two sets of stimulus parameters to determine the one that best improves the health-related quality of life of these patients over a period of 6-weeks. Patients using their assigned device for at least 30 of the 42 possible opportunities will receive the best device for an additional 6-week period.",[188,28],"Long COVID",[190,191],"Medically unexplained illness","Vagus Nerve","2025-08-04",{"date":194,"type":35},"2025-08-08",{"date":196,"type":35},"2024-11-01",{"date":198,"type":21},"2026-12-31",{"name":143,"class":42},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":211,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":43},"100479639","internet-based-treatment-for-patients-suffering-from-severe-functional-somatic-disorders-100479639","NCT05525598","Internet-based Treatment for Patients Suffering From Severe Functional Somatic Disorders","Internet-based Treatment for Patients Suffering From Severe Functional Somatic Disorders: A Randomized Controlled Trial.","OneSTEP","Inclusion Criteria:\n\n* Patients must fulfil the criteria for moderate-severe FSD operationalized as being diagnosed with either single\u002Foligo-organ BDS, with 2 organ systems that are each affected by 3 or more symptoms, or multi-organ BDS, with 3 or 4 organ systems that are each affected by 3 or more symptoms.\n* Patients must have symptom duration \\> 6 months.\n* If older than 25, patients must have been active in the labor market or educational system for at least 12 months during the last 2 years.\n* Patient must have access to a computer or tablet with internet connection.\n* Patient must be able to understand, read, and write Danish fluently.\n\nExclusion Criteria:\n\n* Patients are excluded from participation if they present with severe comorbid somatic or psychiatric disease that is insufficiently treated at the time of assessment and is deemed to constitute a potential barrier for engaging in the treatment.\n* Patients are excluded if they lack motivation to engage in internet-delivered treatment.\n* Patients are excluded if they have poor self-reported IT skills.\n* Patients are excluded if they lack informed consent.\n* Patients are excluded if they have ongoing treatments with opioids and benzodiazepines.\n* Patient's use of psychoactive medications should be stable.","60 Years",{"count":210,"type":21},166,[54],"The aim of this multi-center, two-armed, randomized controlled trial is to assess the effect of a novel internet-based therapist-assisted treatment program \"One step at a time\" designed for the treatment of patients with moderate to severe functional somatic disorder (FSD).\n\nThe trial will enroll 166 patients with FSD who will be randomized (1:1) to either the experimental condition (14 weeks' treatment with \"One step at a time\") or the active control condition (\"GetStarted\"), which is a non-guided internet-based treatment program for patients with FSD. The trial will include patients aged 18-60 years with an established single\u002Foligo-organ or multi-organ FSD diagnosis, with a duration of minimum 6 months. The primary outcome measures will be based on self-reported physical health (SF-36 PPH) and treatment satisfaction (CGI-I). The trial will be considered effective if a higher proportion of patients in the experimental condition report a clinically significant outcome compared with patients in the active control condition at the 3-month follow-up after treatment.",[214,215,27,28,216,217],"Bodily Distress Disorder Moderate","Bodily Distress Disorder Severe","Irritable Bowel Syndrome","Somatization","2025-06-23",{"date":220,"type":35},"2025-06-27",{"date":222,"type":35},"2022-08-24",{"date":224,"type":21},"2026-10-31",{"name":226,"class":42},"University of Aarhus",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":236,"conditions":237,"keywords":238,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":43},"100593688","hydrogen-water-intervention-with-heart-rate-variability-as-an-outcome-biomarker-in-mecfs-100593688","NCT07009691","Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME\u002FCFS","Heart Rate Variability as an Autonomic Marker of Improvement in ME\u002FCFS in a Hydrogen Water Treatment Study","Inclusion Criteria: Meets Institute of Medicine criteria for myalgic encephalomyelitis\u002Fchronic fatigue syndrome -\n\nExclusion Criteria: Medical illness that explains presenting fatigue; Any psychosis.\n\n\\-",{"count":184,"type":21},[54],"The goal of this clinical trial is to learn if the OTC supplement, hydrogen water, works to treat the fatigue-related symptoms and functional limitations in adults with myalgic encephalomyelitis\u002Fchronic fatigue syndrome (ME\u002FCFS). It will also examine if heart rate variability (HRV) can be used to predict who will benefit from the hydrogen water treatment. The main questions it aims to answer are:\n\nDoes the OTC supplement, hydrogen water, work to reduce the fatigue-related symptoms and improve functioning in participants who have ME\u002FCFS?\n\nCan HRV be used to predict who will benefit from treatment with hydrogen water?",[28],[239],"Chronic fatigue syndrome; heart rate variability; treatment; hydrogen water.","2025-06-03",{"date":242,"type":35},"2025-06-08",{"date":244,"type":21},"2025-06-09",{"date":246,"type":21},"2026-05-31",{"name":248,"class":42},"Stony Brook University",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":43},"100496198","the-long-covid-19-wearable-device-study-100496198","NCT05741112","The Long COVID-19 Wearable Device Study","Inclusion Criteria:\n\n* Is at least 18 years old.\n* Has a self\u002Fand or physician diagnosis of:\n* Long COVID (based on the WHO working definition),\n* ME\u002FCFS (myalgic encephalomyelitis \u002F chronic fatigue syndrome, self-diagnosis based on IOM criteria), and\u002For\n* POTS (Postural Orthostatic Tachycardia Syndrome).\n* Is interested in tools to manage ME\u002FCFS, POTS, and\u002For Long COVID symptoms.\n* Owns a wearable device they are willing to use for this study or does not own a device and agrees to utilize a study-provided one.\n* Agrees to wear the device throughout the study period, share the data with the study, and sync data at least weekly.\n* Has access to a smartphone or tablet to enable syncing wearable data and viewing device feedback.\n* Agrees to disclose involvement in other ME\u002FCFS, POTS, and\u002For Long COVID interventions such as medical treatment, self-management, and other interventional studies.\n* Agrees to complete at least 75% of the study surveys.\n\nExclusion Criteria:\n\n* As long as they meet inclusion there is no exclusion",{"count":256,"type":21},100500,[54],"To further characterize Long COVID-19 by collecting data from individuals who already own wearable devices or are provided with a wearable device along with basic and enhanced educational materials to determine if both can improve Long COVID-19 symptom management and post-exertional malaise.",[188,260,261,59,28,262],"Postural Orthostatic Tachycardia Syndrome","Dysautonomia","Long Covid19","2025-05-09",{"date":265,"type":35},"2025-05-11",{"date":267,"type":35},"2023-11-16",{"date":269,"type":21},"2025-12-01",{"name":271,"class":42},"Scripps Translational Science Institute",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":280,"enrollmentInfo":281,"targetDuration":4,"studyType":22,"phases":283,"briefSummary":285,"conditions":286,"keywords":294,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":4},"100534157","early-phase-1-psychoneuromentalism-disorder-a-medical-condition-that-affects-people-with-psychological-impairments-from-health-issues-100534157","NCT06235177","Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues","Psychoneuromentalism Disorder: A Condition Resulting From Behavioral Impairments, Neurodiversity, and Neurobehavioral Dysfunctions Related to the Mental and Emotional State of a Person","PNMD","Inclusion Criteria:\n\n* Clinical Diagnosis of anxiety, schizoaffective disorder, bipolar disorder, ADHD, Dementia, or other psychological issues and disorders; autoimmune disease such as fibromyalgia, lupus, and thyroid disease, neuropathy and chronic fatigue syndrome\n* Must be able to swallow tablets\n\nExclusion Criteria:\n\n* Children under the age of 18\n* Must not be on any blood thinner medications\n* Chronically ill patients","80 Years",{"count":282,"type":21},30,[284],"EARLY_PHASE1","Psychoneuromentalism Disorder is a disorder arising in the mind; that is related to the mental and emotional state of a person. It is the science of mental life. The body has a natural design to heal itself. This is a mental phenomena that cannot be explained, until now.\n\nPsychoneuromentalism Disorder is a new condition resulting from behavioral impairments, neurodiversity, and neurobehavioral dysfunctions that are related to the mental and emotional state of a participant.",[287,288,289,290,291,292,293,28],"Schizoaffective Disorder, Bipolar Type","Bipolar Disorder","ADHD - Combined Type","Dissociative Disorder","Stress Disorder","Dementia","Anxiety",[295,296,297,298,299,293,300,301,162],"Psychology","Neuroscience","Mental Health","Disorder","Stress","Psychoneuromentalism Disorder","ADHD","2024-08-09",{"date":304,"type":35},"2024-08-12",{"date":306,"type":21},"2024-10-10",{"date":308,"type":21},"2025-09-19",{"name":310,"class":42},"The Essence of Integrative Health and Medicine Practice",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":320,"conditions":321,"keywords":322,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":43},"100513593","discovering-trends-in-chronic-fatigue-syndrome-patients-clinical-study-experiences-100513593","NCT05967494","Discovering Trends in Chronic Fatigue Syndrome Patients' Clinical Study Experiences","Assessing Patient Engagement and Understanding in Chronic Fatigue Syndrome Clinical Trials","Inclusion Criteria:\n\n* Signed Written Informed Consent\n* Aged ≥ 18 years old\n* No prior treatment for chronic fatigue syndrome\n\nExclusion Criteria:\n\n* Participant is actively receiving study therapy in another\n* Inability to provide written informed consent\n* Women of childbearing potential without a negative pregnancy test; or women who are lactating.",{"count":319,"type":21},500,"The study seeks to delve into the firsthand experiences of patients diagnosed with chronic fatigue syndrome who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals.\n\nThe data collected from this study will help improve future outcomes for all chronic fatigue syndrome patients as well as those in under-represented demographic groups.",[28],[28],"2023-07-21",{"date":325,"type":35},"2023-08-01",{"date":327,"type":21},"2024-08",{"date":329,"type":21},"2026-08",{"name":331,"class":332},"Power Life Sciences Inc.","INDUSTRY",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":15,"sex":341,"minAge":342,"maxAge":280,"enrollmentInfo":343,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":43},"100484418","monitoring-of-chronic-conditions-in-breast-cancer-100484418","NCT05587777","Monitoring of Chronic Conditions in Breast Cancer","REsearch on BrEast Cancer Induced Chronic Conditions Supported by Causal Analysis of Multi-source Data","REBECCA-1","Inclusion Criteria:\n\n* Breast cancer patients with histologically detectable M0 breast cancer (stage 0-III) who require neoadjuvant or adjuvant endocrine, chemo and \u002F or radiation therapy at least and no more than 3 months before initiation of study.\n* Female breast cancer patients between 19 and 80 years of age.\n* Patients who have increased their life expectancy beyond the first 3 months after starting treatment.\n* Patients who have the ability to understand the protocol and can participate in the follow-up plan.\n* Patients who have an absence of psychological, familial, sociological or geographical condition that potentially impedes compliance with the study protocol and follow-up plan.\n\nExclusion criteria:\n\n* Male breast cancer patients.\n* Patients who do not agree to the study protocol.\n* Patients with a previous cancer diagnosis (excluding skin cancer treated only by surgery).\n* Patients who have previously been treated with some form of chemotherapy \u002F radiation therapy.","FEMALE","19 Years",{"count":344,"type":21},150,"REBECCA-1 is an observational study. Clinical research is undergoing a revolutionary change. The use of electronic patient records (EHR), digital registers, smartphones etc will create \"real-world data\" (RWD) that provides great opportunities for advancing clinical research, but so far this opportunity has been little exploited. The REBECCA -1 study will observe and monitor fatigue in breast cancer survivors. Investigators will use self reported questionnaires (PROM-data), blood tests and objective regulations like the REBECCCA -1 smart watch that will register amount of steps every day, leaving the house, visiting friends, cafes etc. There will be three observational arms; 1.high fatigue, 2. low fatigue and 3. a healthy control arm. After the patients have finished their treatment, they will receive the REBECCA smart watch, a REBECCA app on the smart phone and a REBECCA plus device on their computer, The next offend are also invited to report their evaluation through the same apps. The observational time will be 1 year and comparison between the subjective PROM data , the objective REBECCA watch and the biological samples will be obtained.",[347,28],"Breast Cancer",[349,350],"fatigue","breast cancer","2022-10-19",{"date":353,"type":35},"2022-10-20",{"date":355,"type":35},"2022-06-15",{"date":357,"type":21},"2028-06-15",{"name":359,"class":69},"Helse Stavanger HF"]